Pamidronate results in symptom control of hypertrophic pulmonary osteoarthropathy in cystic fibrosis

Chest. 2002 Apr;121(4):1363-4. doi: 10.1378/chest.121.4.1363.


Hypertrophic pulmonary osteoarthropathy (HPOA) may complicate the advanced lung disease that is associated with cystic fibrosis, resulting in severe joint pain and early-morning stiffness. Symptoms are usually controlled with the administration of nonsteroidal anti-inflammatory drugs, physiotherapy, and, on occasions, oral corticosteroids. This report describes a case of refractory HPOA with complete remission following the administration of IV pamidronate, which is a potent inhibitor of osteoclastic bone resorption. Symptom relief resulted for up to 3 months, but repeated courses of pamidronate have been required to maintain symptom control.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Ankle / diagnostic imaging
  • Cystic Fibrosis / diagnostic imaging
  • Cystic Fibrosis / drug therapy*
  • Diphosphonates / therapeutic use*
  • Female
  • Humans
  • Infusions, Intravenous
  • Osteoarthropathy, Secondary Hypertrophic / diagnostic imaging
  • Osteoarthropathy, Secondary Hypertrophic / drug therapy*
  • Osteoclasts / drug effects
  • Pamidronate
  • Radiography


  • Diphosphonates
  • Pamidronate